Original Investigation |

New Oral Anticoagulants and the Risk of Intracranial Hemorrhage:  Traditional and Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials of New Oral Anticoagulants in Atrial Fibrillation

Saurav Chatterjee, MD1; Partha Sardar, MD2; Giuseppe Biondi-Zoccai, MD3; Dharam J. Kumbhani, MD, SM, MRCP4
[+] Author Affiliations
1Division of Cardiology, Brown University, Providence, Rhode Island
2Department of Medicine, New York Medical College–Metropolitan Hospital Center, New York
3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
4Division of Cardiology, University of Texas Southwestern Medical Center, Dallas
JAMA Neurol. 2013;70(12):1486-1490. doi:10.1001/jamaneurol.2013.4021.
Text Size: A A A
Published online

Importance  Randomized studies have shown a decreased risk of intracranial hemorrhage (ICH) with use of novel oral anticoagulants (NOACs). However, it is unclear whether the magnitude of benefit is similar for all NOACs currently available.

Objective  To perform a systematic review and meta-analysis to quantitatively assess the rates of ICH within the framework of both conventional and Bayesian statistics.

Data Sources  The MEDLINE, CENTRAL, CINAHL, and EBSCO databases, supplemented with conference abstracts, were searched up to December 1, 2012, with no language restriction.

Study Selection  Randomized trials comparing NOACs vs a comparator and reporting on ICH events.

Data Extraction and Synthesis  The NOACs were pooled to perform a comparison with all comparators and among themselves in both traditional frequentist and Bayesian random-effects models using vague priors and Markov chain Monte Carlo simulation with Gibbs sampling, calculating pooled odds ratios and associated 95% confidence intervals as well as numbers needed to treat and 95% credible intervals for the Bayesian analysis.

Main Outcomes and Measures  Intracranial hemorrhage events associated with NOACs in comparison with comparators, expressed as odds ratios.

Results  Six studies (1 administering dabigatran etexilate mesylate, 2 administering rivaroxaban, and 3 administering apixaban) enrolling a total of 57 491 patients were included for analysis. The NOACs significantly reduced the risk of ICH against all comparators (odds ratio = 0.49; 95% CI, 0.36-0.65). Each of the 3 drugs reduced the risk of ICH, with Bayesian indirect comparison analysis not revealing a significant credible difference between the specific medications.

Conclusions and Relevance  Novel oral anticoagulants are uniformly associated with an overall reduced risk of ICH when used for stroke prevention in atrial fibrillation. Any of the currently available NOACs can be considered first line for patients at high risk for ICH.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours


Place holder to copy figure label and caption
Odds Ratios of Intracranial Hemorrhage With Use of Novel Oral Anticoagulants

M-H indicates Mantel-Haenszel; NOACs, novel oral anticoagulants.

Graphic Jump Location





You need to register in order to view this quiz.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario